Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.60 |
| ▸ | HTT | P42858 | 4/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.60 |
| ▸ | RAF1 | P04049 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19523694 | 1.00 | IRAK4 (0.74) | IRAK4SMN1; SMN2MAPK1HTTMEN1 | |
| SCHEMBL13644124 | 0.90 | IRAK4 (0.73) | IRAK4SMN1; SMN2MAPK1HTTMEN1 | |
| SCHEMBL10326030 | 0.88 | IRAK4 (0.73) | IRAK4SMN1; SMN2MAPK1HTTMEN1 | |
| SCHEMBL10326067 | 0.88 | IRAK4 (0.73) | IRAK4SMN1; SMN2MAPK1HTTMEN1 | |
| SCHEMBL10326031 | 0.88 | IRAK4 (0.73) | IRAK4SMN1; SMN2MAPK1HTTMEN1 | |
| SCHEMBL13164961 | 0.87 | IRAK4 (0.72) | IRAK4SMN1; SMN2MAPK1HTTMEN1 | |
| SCHEMBL10343739 | 0.85 | IRAK4 (1.00) | IRAK4SMN1; SMN2MAPK1HTTMEN1 | |
| SCHEMBL18962386 | 0.85 | IRAK4 (0.69) | IRAK4SMN1; SMN2MAPK1HTTMEN1 | |
| SCHEMBL6642717 | 0.78 | SMN1; SMN2 (0.60) | IRAK4SMN1; SMN2MAPK1HTTMEN1 | |
| SCHEMBL10343465 | 0.78 | IRAK4 (0.60) | IRAK4SMN1; SMN2MAPK1HTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3239154-A1 | IRAK INHIBITORS AND USES THEREOF | Nimbus Iris, Inc. (US) | 2017-11-01 | — | — | EP | disclosed |
| EP-3239154-A1 | IRAK INHIBITORS AND USES THEREOF | Nimbus Iris, Inc. (US) | 2017-11-01 | — | — | EP | disclosed |
| EP-2663312-B1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS INC (US) | 2017-10-11 | — | — | EP | disclosed |
| EP-2663312-B1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS INC (US) | 2017-10-11 | — | — | EP | disclosed |
| US-20160296524-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS INC (US) | 2016-10-13 | — | — | US | disclosed |
| US-20160296524-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS INC (US) | 2016-10-13 | — | — | US | disclosed |
| US-20160296524-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS INC (US) | 2016-10-13 | — | — | US | disclosed |
| US-9340554-B2 | IRAK inhibitors and uses thereof | NIMBUS IRIS, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340554-B2 | IRAK inhibitors and uses thereof | NIMBUS IRIS, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340554-B2 | IRAK inhibitors and uses thereof | NIMBUS IRIS, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20150025093-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2015-01-22 | — | — | US | disclosed |
| US-20150025093-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2015-01-22 | — | — | US | disclosed |
| US-20150025093-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2015-01-22 | — | — | US | disclosed |
| US-8703941-B2 | IRAK inhibitors and uses thereof | NIMBUS IRIS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| EP-2663312-A1 | IRAK INHIBITORS AND USES THEREOF | Nimbus Iris, Inc. (US) | 2013-11-20 | — | — | EP | disclosed |
| US-20120283238-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120283238-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120283238-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2012-11-08 | — | — | US | disclosed |
| WO-2012097013-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2012-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025093-A1 | IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | IRAK4 4/4885SMN1; SMN2 2457/4885MAPK1 780/4885 |
| US-20160296524-A1 | IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | IRAK4 4/4885SMN1; SMN2 2457/4885MAPK1 780/4885 |
| US-20120283238-A1 | IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | IRAK4 4/4885SMN1; SMN2 2457/4885MAPK1 780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.